Are Compounded Semaglutide and Tirzepatide Safe? Understanding the FDA Warning

What the FDA Warning Actually Says

The FDA has issued multiple communications warning consumers and healthcare providers about risks associated with compounded versions of semaglutide and tirzepatide. These warnings are not theoretical. They reflect real adverse event reports, product seizures, and laboratory analyses showing problems with compounded formulations.

Timeline of FDA Actions

The agency's first major public statement came in June 2023, when it warned that compounded semaglutide products had not been evaluated for safety, efficacy, or quality. By late 2023, the FDA had received adverse event reports involving nausea, vomiting, and gastrointestinal complications severe enough to require emergency care. In some cases, patients received products with inaccurate concentrations of the active ingredient.

Products Seized and Pharmacies Cited

In 2024, the FDA took enforcement action against multiple compounding operations, including issuing warning letters and, in some cases, coordinating product seizures. The agency specifically cited concerns about sterility assurance, potency accuracy, and misleading marketing that implied FDA approval where none existed [1].

Scope of the Warning

The FDA's position is clear: compounded drugs are not FDA-approved, and no compounded version of semaglutide or tirzepatide has undergone the rigorous clinical testing required for approval. This applies to all dosage forms, including subcutaneous injections, sublingual tablets, and troches [2].

Why Compounded GLP-1 Medications Exist

Brand-name semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have experienced unprecedented demand since 2022. At peak shortage, millions of patients could not fill prescriptions through standard pharmacy channels. Compounding pharmacies stepped in to fill that gap.

The Drug Shortage Exception

Under the Federal Food, Drug, and Cosmetic Act, sections 503A and 503B permit pharmacies to compound copies of FDA-approved drugs during an active shortage listed by the FDA. This legal pathway allowed compounders to produce semaglutide and tirzepatide formulations while supply was constrained.

What Changed in 2024 and 2025

The FDA removed semaglutide from its shortage list in February 2024, and tirzepatide followed in October 2024. Once a drug leaves the shortage list, the legal basis for compounding copies narrows significantly. Pharmacies that continue producing these drugs face potential enforcement action, though the FDA has generally allowed a transition period for patients already receiving compounded products [3].

Cost as a Driver

A month's supply of Wegovy carries a list price of approximately $1,349. Zepbound lists at around $1,060 per month. By comparison, compounded semaglutide has been available for $150 to $500 per month. This price gap has driven substantial patient demand, particularly among those without insurance coverage for weight management medications.

The Semaglutide Sodium Problem

One of the most significant safety concerns involves the chemical form of the active ingredient used by many compounding pharmacies. This is not a minor technical distinction. It represents a fundamentally different molecule.

Base vs. Salt Form

FDA-approved semaglutide products (Ozempic, Wegovy, Rybelsus) use semaglutide in its base form. Many compounding pharmacies have instead sourced semaglutide sodium, a sodium salt version of the molecule. The FDA has stated that semaglutide sodium is a different active ingredient than what was studied in the clinical trials that established safety and dosing for the approved products [4].

Why the Salt Form Matters

The pharmacokinetic profile of semaglutide sodium has not been characterized through clinical trials. Differences in salt form can affect absorption rate, bioavailability, and peak plasma concentration. A patient injecting what they believe is 0.5 mg of semaglutide may be receiving a different effective dose if the sodium salt behaves differently in subcutaneous tissue.

Sourcing and Purity Questions

Bulk semaglutide sodium is typically sourced from chemical suppliers, some of which lack FDA registration or current Good Manufacturing Practice (cGMP) compliance. The Endocrine Society noted in a 2024 statement that the provenance and purity of bulk active pharmaceutical ingredients used in compounding may not meet the standards required for injectable drug products [5].

Sterility and Potency Risks

Injectable medications must meet strict sterility standards. A contaminated injection can cause local infection, systemic sepsis, or death. The manufacturing controls that Novo Nordisk and Eli Lilly maintain at their production facilities do not automatically apply to compounding pharmacies.

USP 797 Compliance

United States Pharmacopeia (USP) Chapter 797 sets the standard for sterile compounding. It specifies requirements for cleanroom environments, personnel training, environmental monitoring, and beyond-use dating. Not all pharmacies performing sterile compounding meet USP 797 requirements. State board enforcement varies widely [6].

Potency Variability

FDA laboratory analysis of seized compounded semaglutide products has revealed potency outside acceptable ranges. Some products contained substantially less active ingredient than labeled, meaning patients received sub-therapeutic doses. Others contained more, increasing the risk of severe gastrointestinal side effects, including pancreatitis, which the STEP-1 trial (N=1,961) identified as a rare but serious risk even at standard doses [7].

Reported Adverse Events

The FDA Adverse Event Reporting System (FAERS) has logged reports of patients experiencing adverse reactions to compounded GLP-1 products, including severe hypoglycemia, injection site infections, and gastrointestinal events requiring hospitalization. Exact numbers are difficult to pin down because FAERS relies on voluntary reporting, which captures an estimated 1% to 10% of actual events according to published analyses [8].

503A vs. 503B: Understanding Pharmacy Types

The regulatory framework for compounding in the United States divides pharmacies into two categories, each with different oversight levels and capabilities.

503A Traditional Compounding Pharmacies

Section 503A pharmacies compound medications based on individual patient prescriptions. They are regulated primarily by state boards of pharmacy. They do not need to register with the FDA, and their products are exempt from FDA manufacturing requirements. Quality assurance depends heavily on the individual pharmacy's practices and state-level inspection rigor.

503B Outsourcing Facilities

Section 503B outsourcing facilities voluntarily register with the FDA and are subject to FDA inspection using cGMP standards. They can produce larger batches without individual prescriptions. They must report adverse events to the FDA. They undergo more rigorous quality testing, including potency and sterility verification of finished products [9].

Which Is Safer?

Neither category guarantees safety equivalent to FDA-approved products. A 503B facility operating under full cGMP compliance with third-party testing comes closer, but it still produces a product that has not been through clinical trials. The American Association of Clinical Endocrinology (AACE) has stated that patients using compounded GLP-1 agonists should be informed that these products "lack the quality assurance of FDA-approved medications" [10].

How to Evaluate a Compounding Pharmacy

Patients who, in consultation with their prescriber, decide to use a compounded GLP-1 product should apply specific criteria to evaluate the pharmacy.

Accreditation and Licensing

Look for accreditation from the Pharmacy Compounding Accreditation Board (PCAB), a division of the Accreditation Commission for Health Care. PCAB-accredited pharmacies undergo voluntary inspection against quality standards that exceed most state board requirements. At minimum, verify that the pharmacy holds a valid state license and, if operating as a 503B facility, confirm FDA registration status [11].

Questions to Ask

Request a Certificate of Analysis (COA) for the specific batch of medication. The COA should include potency testing results, sterility testing results, endotoxin testing for injectables, and beyond-use dating supported by stability studies. Ask whether the pharmacy uses semaglutide base or semaglutide sodium. Ask whether the bulk active ingredient comes from an FDA-registered supplier.

Red Flags

Avoid pharmacies that sell directly to consumers without a prescription. Avoid products marketed on social media with before-and-after photos and no mention of risks. Avoid any pharmacy that claims its compounded product is "the same as" or "equivalent to" Ozempic, Wegovy, Mounjaro, or Zepbound.

What the Medical Societies Say

Major endocrine and obesity medicine organizations have weighed in with consistent messaging: compounded GLP-1 agonists carry risks that FDA-approved products do not.

Endocrine Society Position

The Endocrine Society published a position statement urging patients to use FDA-approved GLP-1 receptor agonists whenever possible. The statement specifically flagged concerns about salt form differences, potency variability, and the absence of clinical trial data for compounded formulations [5].

Dr. John Buse, former president of the American Diabetes Association, stated in a 2024 interview: "We have no data on compounded semaglutide. Zero randomized trials. We are asking patients to trust a product that has never been tested in humans in the form they are receiving it."

Obesity Medicine Association Guidance

The Obesity Medicine Association (OMA) has recommended that prescribers document informed consent when patients choose compounded GLP-1 products, including acknowledgment that the product is not FDA-approved and that adverse events may differ from those observed in clinical trials of branded products.

Dr. Angela Fitch, then-president of OMA, noted: "The efficacy data we cite from SURMOUNT and STEP trials apply to specific formulations made under specific manufacturing conditions. Compounded versions are a different product."

Clinical Considerations for Prescribers

Healthcare providers prescribing or considering compounded GLP-1 agonists face specific clinical and medicolegal considerations.

Informed Consent

Document that the patient understands the product is not FDA-approved, that the salt form may differ from studied formulations, and that manufacturing quality is not guaranteed to the same standard as brand-name products. This documentation protects both patient and prescriber.

Monitoring Recommendations

Patients on compounded GLP-1 products may warrant closer monitoring than those on FDA-approved versions. Consider more frequent follow-up during dose titration, given the uncertainty around potency consistency between batches. Monitor for injection site reactions, which may indicate sterility issues. Standard metabolic monitoring (HbA1c, lipid panel, renal function) should follow the same intervals as for FDA-approved products [12].

Transition Planning

For patients currently on compounded semaglutide or tirzepatide, develop a plan for transitioning to FDA-approved products as supply normalizes and access pathways expand. Novo Nordisk's patient savings program and Eli Lilly's LillyDirect platform have both reduced out-of-pocket costs for eligible patients to as low as $25 per month for commercially insured individuals.

The Regulatory Outlook

The legal field for compounded GLP-1 medications continues to shift. Several lawsuits have been filed by compounding pharmacies challenging the FDA's authority to restrict compounding after shortage resolution.

Ongoing Legal Challenges

In early 2025, multiple 503A and 503B pharmacies filed suit in federal court arguing that the FDA's shortage resolution determination was premature and that patient access would be harmed by restricting compounding. Courts have issued mixed rulings, with some granting temporary restraining orders allowing continued compounding while litigation proceeds [13].

State-Level Variation

Some states have enacted or proposed legislation that would permit compounding of GLP-1 agonists regardless of federal shortage status. This creates a patchwork regulatory environment where legality depends on geography. Patients and prescribers should consult their state board of pharmacy for current rules.

What to Expect

The FDA has signaled that enforcement will prioritize pharmacies marketing directly to consumers, those making unsubstantiated safety claims, and those with documented quality failures. Pharmacies operating within 503B requirements and producing for licensed prescribers may face less immediate scrutiny, but the long-term trajectory points toward tighter regulation of compounded versions of high-demand branded biologics.

Patients currently using compounded semaglutide or tirzepatide should confirm their pharmacy's 503A or 503B status, request batch-specific Certificates of Analysis, and schedule a prescriber visit to discuss whether transitioning to an FDA-approved formulation is appropriate for their clinical situation.